Mcl-1 inhibitor; disrupts Mcl-1-Bim interaction and induces Mcl-1 proteasomal degradation. Exhibits no effect on Bcl-XL-Bim interaction. Selectively induces apoptosis in Mcl-1-dependent K562 leukemia cells. Sensitizes K562 and Raji cells to ABT-737-induced apoptosis.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 510.15. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.96 mL||9.8 mL||19.6 mL|
|5 mM||0.39 mL||1.96 mL||3.92 mL|
|10 mM||0.2 mL||0.98 mL||1.96 mL|
|50 mM||0.04 mL||0.2 mL||0.39 mL|
References are publications that support the products' biological activity.
Doi et al (2012) Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J.Biol.Chem. 287 10224 PMID: 22311987
Pandey et al (2013) Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PLoS ONE 8 e78570 PMID: 24223823
If you know of a relevant reference for Maritoclax, please let us know.
View Related Products by Product Action
Keywords: Maritoclax, supplier, Mcl-1, inhibitors, inhibits, apoptosis, proapoptotic, leukemia, ABT737, marinopyrroleA, Bcl-2, Family, Bcl-2, Family, Tocris Bioscience
Citations for Maritoclax
Citations are publications that use Tocris products.
Currently there are no citations for Maritoclax. Do you know of a great paper that uses Maritoclax from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Programmed Cell Death Poster
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.